Cargando…
Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy
Cancer accounts for numerous deaths each year, and it is one of the most common causes of death worldwide, despite many breakthroughs in the discovery of novel anticancer candidates. Each new year the FDA approves the use of new drugs for cancer treatments. In the last years, the biological targets...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776383/ https://www.ncbi.nlm.nih.gov/pubmed/36551271 http://dx.doi.org/10.3390/biom12121843 |